Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07126158 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT07126158 is a Phase 2 study that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 36 participants.
The verdict
NCT07126158, a Phase 2 study, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
Interventions
- DRUG Avutometinib
- DRUG Defactinib
- RADIATION Stereotactic body radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-04-10 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07126158
The ClinicalTrials.gov registry entry for NCT07126158 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Avutometinib is the first listed.
NCT07126158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07126158 about?
NCT07126158 is a clinical study titled "Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma". Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
What is the current status of trial NCT07126158?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2026-04-10. Estimated completion is 2030-04-30.
What interventions are being tested in trial NCT07126158?
The interventions under investigation include: Avutometinib (DRUG), Defactinib (DRUG), Stereotactic body radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT07126158?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.